Clinical trial NCT04463849: Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients
Official title: Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID19
BETA-CELL FUNCTION
Lead sponsor: University of Milan
Sponsor class: OTHER
Collaborators: name: Luigi Sacco University Hospital
First posted: 2020-07-09
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: In recent months, a new coronavirus, SARS-CoV-2, has been identified as the cause of a serious lung infection named COVID-19 by the World Health Organization. This virus has spread rapidly among the nations of the world and it is the cause of a pandemic and a global health emergency. There is still very little scientific evidence on the virus, however epidemiological data suggest that one of the most frequent comorbidities is diabetes, along with hypertension and heart disease. There is no scientific evidence on the possible effects of this infection on the function of the β cell and on glycemic control. Clinical evidence seems to suggest that COVID-19 infection mostly affects the respiratory system, and an acute worsening of glycemic compensation is not described as generally observed in bacterial pneumonia. However, previous work on acute respiratory syndromes (SARS) caused by similar coronaviruses, had described that the infection has multi-organ involvement related to the expression of the SARS coronavirus receptor, the angiotensin 2 converting enzyme, in different organs, especially at the level of endocrine pancreatic tissue. In the population of this previous work, glucose intolerance and fasting hyperglycaemia have been described and in 37 of 39 diabetic patients examined, a remission of diabetes was observed three years after the infection. It is possible that the coronaviruses responsible for SARS may enter the pancreatic islets using the angiotensin 2 converting enzyme receptor, expressed at the level of the endocrine pancreas, thus causing diabetes. Additionally, previous literature on coronavirus infections (SARS and MERS or Middle-East Respiratory Syndrome) suggested that diabetes could worsen the evolution of the disease. In particular, in case of Middle-East Respiratory Syndrome-CoV infection, diabetic mice had a more prolonged serious illness and a delay in recovery regardless of the viremic titer. This could probably be due to a dysregulation of the immune response, which results in more serious and prolonged lung disease.

There are currently no data on pancreatic beta cell function in patients with COVID-19.

Detailed description: The project is monocentric, interventional, non-pharmacological, non-profit. Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal blood glucose and no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance. Patients will be compared to a control group of healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance. Patients will be also compared with a group of patients with type 2 diabetes but without COVID-19. Once the informed consent has been signed, the clinical parameters and biochemical parameters will be collected according to the time points provided by the protocol in positive COVID-19 patients, in healthy volunteers and in patients with type 2 diabetes.

COVID-19 positive patients and healthy controls as well as patients with type 2 diabetes, will undergo a stimulation test of β-cell function (evaluation of the secretive response of insulin to the stimulation test with arginine infusion) and the monitoring of glycemic values through a professional retrospective continuous glucose monitoring. For the test, an infusion solution containing 25% arginine hydrochloride will be used, arginine is an insulinogenic amino acid, useful to verify the possible existence of damage to the cellular beta function induced by COVID-19 infection, clinically observable with changes in insulin secretory response. Given the usefulness of the test, performed for diagnostic purposes, this protocol is identified as "non-pharmacological". The test is contraindicated only in patients with severe hepatic and renal insufficiency, in all other subjects the side effects are minimal and spontaneous resolution before the end of the test (flushing 33%, oral paraesthesia 46%, nausea 12%, dizziness 14%). For the stimulation test with arginine infusion, after the basal sampling at (0 minutes), an intravenous injection of arginine 5 grams will be practiced in 60 seconds followed by serial withdrawals at +2, +5, +10 and +30 minutes. The following analytes will be assayed on the basal sample: glycosylated hemoglobin, glycaemia, insulin, pro-insulin, C-peptide, glucagon, serum inflammatory cytokines (Il1β, IL-2, IL-6, IL-7, IL-10, TNF- α, IFN-γ, MIP-1β, MCP-1, GM-CSF, G-CSF Insulin, C-peptide and glucagon will be dosed on all points of the curve.

Eligibility criteria: Inclusion criteria for COVID-19 positive patients

* Male and female patients with COVID19 and normal basal blood sugar, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance
* Age\> 18 years and \<80 years
* Availability to informed consent and corporate privacy

Inclusion criteria for healthy subjects

* Male and female patients not affected by COVID19, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance
* Age\> 18 years and \<80 years
* Availability to informed consent and corporate privacy

Exclusion criteria for COVID-19 positive patients

* Age \<18 years
* Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance
* Severe liver failure
* Severe kidney failure

Exclusion criteria for healthy subjects

* Age \<18 years
* Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance
* Positivity to the nasopharyngeal swab for SARS-CoV-2
* Severe liver failure
* Severe kidney failure

Inclusion criteria for T2D patients

* Male and female patients not affected by COVID19 with a diagnosis of type 2 diabetes
* Age\> 18 years and \<80 years
* Availability to informed consent and corporate privacy

Exclusion criteria for T2D patients

* Age \<18 years
* Positivity to the nasopharyngeal swab for SARS-CoV-2
* Severe liver failure
* Severe kidney failure

Primary outcomes:
measure: Serum β - cellular function index insulin levels
timeFrame: all data were collected at Visit 1, 12 months
measure: Serum β - cellular function index C-peptide levels
timeFrame: all data were collected at Visit 1, 12 months
measure: Serum β - cellular function HOMA-β index
timeFrame: all data were collected at Visit 1, 12 months
measure: Serum β - cellular function pro-insulin/insulin ratio
timeFrame: all data were collected at Visit 1, 12 months
measure: Evaluation of the secretory response of insulin to the arginine stimulation test
timeFrame: all data were collected at Visit 1, 12 months
measure: Percentage of patients with preserved β cells function
timeFrame: all data were collected at Visit 1, 12 months
Secondary outcomes:
measure: Glucose values
timeFrame: all data were collected at Visit 1, 12 months
measure: Values of continuous glucose monitoring
timeFrame: all data were collected at Visit 1 and after 7 days, 12 months
measure: Changes in the inflammatory marker interleukin 1-β
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker interleukin IL-2
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker interleukin IL-6
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker interleukin IL-7
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker interleukin IL-10
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker tumor necrosis factor-α
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker interferon gamma
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker macrophage inflammatory protein-1β
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker monocyte chemoattractant protein-1
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor
timeFrame: all data were collected at Visit 1, 12 months
measure: Changes in the inflammatory marker granulocyte colony-stimulating factor
timeFrame: all data were collected at Visit 1, 12 months
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Sacco University Hospital
state: MI
Study officials:
References:
citation: Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med. 2020 Feb 20;9(2):575. doi: 10.3390/jcm9020575.
citation: Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019 Oct 17;4(20):e131774. doi: 10.1172/jci.insight.131774.
citation: Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
citation: Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010 Sep;47(3):193-9. doi: 10.1007/s00592-009-0109-4. Epub 2009 Mar 31.
citation: Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health beta-Cell Project Team. Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of beta-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.
citation: Brandle M, Lehmann R, Maly FE, Schmid C, Spinas GA. Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation. Diabetes Care. 2001 Jul;24(7):1253-8. doi: 10.2337/diacare.24.7.1253.
citation: Bolla AM, Loretelli C, Montefusco L, Finzi G, Abdi R, Ben Nasr M, Lunati ME, Pastore I, Bonventre JV, Nebuloni M, Rusconi S, Santus P, Zuccotti G, Galli M, D'Addio F, Fiorina P. Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19. Diabetes Metab Res Rev. 2022 Oct;38(7):e3565. doi: 10.1002/dmrr.3565. Epub 2022 Jul 22.
citation: Ben Nasr M, D'Addio F, Montefusco L, Usuelli V, Loretelli C, Rossi A, Pastore I, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Clark P, Nebuloni M, Baldi G, Finzi G, Folli F, Zuccotti GV, Galli M, Herold KC, Fiorina P. Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets. Diabetes. 2022 Jul 1;71(7):1579-1590. doi: 10.2337/db21-0926.